Hemodynamic stress-induced cardiac remodelling is not modulated by ablation of phosphodiesterase 4D interacting

Belal A Mohamed1,2, Manar Elkenani1,2, Sherok Mobarak1

  • 1Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany.

Insights

Phosphodiesterase 4D interacting protein (Pde4dip) deficiency did not alter adverse cardiac remodeling in mice subjected to hemodynamic overload. Pde4dip does not appear to be a key factor in heart adaptation to stress.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Adrenergic stimulation activates protein kinase A (PKA) in the heart, influencing intracellular calcium handling.
  • A kinase anchoring proteins (AKAPs), like phosphodiesterase 4D interacting protein (Pde4dp), scaffold PKA to its substrates.
  • Pde4dip expression changes with hemodynamic overload, a condition causing cardiac stress.

Purpose of the Study:

  • To investigate the role of Pde4dp in adverse cardiac remodeling following hemodynamic stress.
  • To determine if Pde4dp deficiency impacts cardiac structure, function, and pathology after volume or pressure overload.

Main Methods:

  • Generated homozygous Pde4dip knockout (KO) mice using CRISPR-Cas9 technology.
  • Subjected KO and wild-type (WT) mice to aortocaval shunt (volume overload) or transthoracic aortic constriction (pressure overload).
  • Assessed mortality, cardiac structure, function, and pathological remodeling post-injury.

Main Results:

  • Pde4dp protein levels were differentially regulated in WT hearts under volume (downregulated) versus pressure (upregulated) overload.
  • Mortality rates were similar between Pde4dp-KO and WT mice following both shunt and TAC procedures.
  • Cardiac hypertrophy, dilatation, dysfunction, cardiomyocyte hypertrophy, fibrosis, and gene expression changes did not differ between genotypes after hemodynamic stress.

Conclusions:

  • Despite altered Pde4dp protein expression in stressed hearts, Pde4dp deficiency does not influence adverse cardiac remodeling in response to hemodynamic volume or pressure overload.
  • Pde4dp is not a critical mediator of cardiac adaptation or maladaptation to significant hemodynamic stress.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
497
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
43